Nuclear receptor-binding SET domain protein 1 (NSD1) is a large, multi-domain histone methyltransferase that catalyzes the mono- and di-methylation of lysine 36 on histone H3 (H3K36), and may also act on histone H4 at lysine 20. Containing a catalytic SET domain, PWWP domains, PHD fingers, and interaction motifs for nuclear receptors, NSD1 is a critical chromatin regulator involved in transcriptional activation and repression. It regulates gene expression during embryonic development and controls growth, and is implicated in multiple diseases when mutated or dysregulated. NSD1 loss-of-function causes Sotos syndrome, a childhood overgrowth disorder, while chromosomal rearrangements involving NSD1 are oncogenic in acute myeloid leukemia and other cancers. NSD1 acts both as a tumor suppressor and oncogene, depending on cellular context, and is an emerging epigenetic target in oncology research.
Other names
Histone-lysine N-methyltransferase, H3 lysine-36 specificLysine N-methyltransferase 3BKMT3BARA267Nuclear receptor SET domain-containing protein 1Androgen receptor coactivator 267 kDa proteinSOTOSSOTOS1
02
Mechanism of action
Drugs targeting NSD1 (if developed) would likely act as histone methyltransferase inhibitors, blocking methylation of H3K36 to influence gene expression and chromatin state.
03
Biological functions
Histone methylation (mono- and di-methylation at H3K36, also activity at H4K20)Transcriptional regulation (co-activator and co-repressor functions)Chromatin remodelingRegulation of gene expression during developmentMaintenance of genomic integrityRegulation of cell growth, DNA repair, and differentiation
04
Disease associations
Cancer (e.g., acute myeloid leukemia, breast cancer, melanoma, neuroblastoma, glioblastoma)Developmental disorders (notably Sotos syndrome)Overgrowth syndromesNeurodevelopmental disease
05
Safety considerations
Targeting NSD1 may pose a risk of disrupting normal development, as it is critical for growth, neurodevelopment, and homeostasis.NSD1 loss-of-function is associated with overgrowth, learning disabilities, and developmental delay (Sotos syndrome).Complete systemic inhibition could increase risk of genomic instability and unintended epigenetic effects.
06
Interacting drugs
No approved small molecule inhibitors or drugs are noted to directly target NSD1. Experimental inhibitors of NSD1 and related methyltransferases are under investigation, but not clinically advanced. No commonly used drugs interact directly with NSD1 per current clinical knowledge.
07
Biomarkers
NSD1 mutations (for Sotos syndrome diagnosis or stratification)NSD1 gene fusions with NUP98 (in acute myeloid leukemia)Loss-of-function or promoter methylation status (as a tumor suppressor marker in certain cancers)
Beyond the preview
Go deeper on Nuclear receptor-binding SET domain protein 1 (NSD1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nuclear receptor-binding SET domain protein 1 (NSD1).